University of California

Other

California Institute of Technology

Seth M Cohen

David Thomas Puerta

Kenneth N Raymond

Jide Xu

Stephane Petoud

Jana A Lewis

Christian Perez

Raymond J Deshaies

Robert G Uzzo

Jing Li

Alexander Kutikov

Vladimir Kolenko

Ervin Teper

Yuyong Ma

Jody L Major Jourden

Cy V Credille

Zhenjie Zhang

Jean-Philippe Monserrat

There are provided inter alia metalloenzyme inhibitors, such as inhibitors of influenza A RNA dependent RNA polymerase PA subunit endonuclease, and methods of synthesis and use of the same.

Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease

Disclosed herein, inter alia, are polymerized metal organic framework compositions and polymer compositions, and methods of making and using the same.

Polymer-metal organic framework materials and methods of using the same

Candidate compounds for specific inhibition of Rpn11 are represented by Formula 1 where each of R, R, R, R, R, and Ris independently selected from hydrogen (H), substituted and unsubstituted alkyl groups, carboxyl groups, or substituted and unsubstituted carboxyamides.

Inhibitors of RPN11

Provided herein are ROS-sensitive prodrug compositions and methods of treating ROS-associated diseases by administering the ROS-sensitive prodrug compositions.

Reactive oxygen species-based prodrugs

The invention provides zinc chelating agents and formulations thereof that deplete XIAP in cancer cells and sensitize the cells to apoptosis-inducing agents. The invention provides methods for sensitizing apoptosis-resistant cancer cells to apoptosis-inducing agents, as well as methods for treating a subject with a combined therapy of a zinc chelating agent and an apoptosis-inducing agent.

Zinc chelating agents for depleting XIAP and sensitizing tumor cells to apoptosis

Set forth herein, inter alia, are compositions and methods for treating diseases with prodrugs. Provided herein are prodrug compositions for inhibiting the function of proteins, compositions and methods for treating diseases associated with oxidative compounds, oxidatively-sensitive prodrugs of inhibitors of metalloproteases. and methods of inhibiting metalloproteases using oxidatively-sensitive prodrugs.

Stimulus-triggered prodrugs

The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R, R, R, and Ris individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

Metalloprotein inhibitors

The present invention relates to metalloprotein inhibitors comprising: wherein X is O or S and each R, R, R, and Ris individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R, R, R, and Ris individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity. 

The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention.

Phthalamide-lanthanide complexes for use as luminescent markers

The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one salicylamidyl moiety. Also provided are probes incorporating the salicylamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention.

Growing community of inventors

Carlsbad, CA, United States of America

Seth M Cohen